Evidence map›Paper›PMID 32152351›Full record

ArticleScientific reports2020

Dasatinib exacerbates splenomegaly of mice inoculated with Epstein-Barr virus-infected lymphoblastoid cell lines.

Ryutaro Kotaki, Masaharu Kawashima, Yuichiro Yamamoto, Hiroshi Higuchi, Etsuko Nagashima, Natsumi Kurosaki, Masako Takamatsu, Yara Yukie Kikuti, Ken-Ichi Imadome, Naoya Nakamura and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Ryutaro Kotaki *Department of Hematological Malignancy, Institute of Medical Science, Tokai University, Shimokasuya 143, Isehara, Kanagawa, Japan.
Masaharu Kawashima *Department of Hematological Malignancy, Institute of Medical Science, Tokai University, Shimokasuya 143, Isehara, Kanagawa, Japan.
Yuichiro Yamamoto *Department of Hematological Malignancy, Institute of Medical Science, Tokai University, Shimokasuya 143, Isehara, Kanagawa, Japan.
Hiroshi HiguchiDepartment of Hematological Malignancy, Institute of Medical Science, Tokai University, Shimokasuya 143, Isehara, Kanagawa, Japan.
Etsuko NagashimaDepartment of Hematological Malignancy, Institute of Medical Science, Tokai University, Shimokasuya 143, Isehara, Kanagawa, Japan.
Natsumi KurosakiDepartment of Hematological Malignancy, Institute of Medical Science, Tokai University, Shimokasuya 143, Isehara, Kanagawa, Japan.
Masako TakamatsuDepartment of Hematological Malignancy, Institute of Medical Science, Tokai University, Shimokasuya 143, Isehara, Kanagawa, Japan.
Yara Yukie KikutiDepartment of Pathology, Tokai University School of Medicine, Shimokasuya 143, Isehara, Kanagawa, Japan.
Ken-Ichi ImadomeDepartment of Infectious Diseases, National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan.
Naoya NakamuraDepartment of Pathology, Tokai University School of Medicine, Shimokasuya 143, Isehara, Kanagawa, Japan.
Ai KotaniDepartment of Hematological Malignancy, Institute of Medical Science, Tokai University, Shimokasuya 143, Isehara, Kanagawa, Japan. aikotani@k-lab.jp.
Tokai University · JPJapan Science and Technology Agency · JPNational Center For Child Health and Development · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Latent infection of Epstein-Barr virus (EBV) is associated with a poor prognosis in patients with B cell malignancy. We examined whether dasatinib, a multi kinase inhibitor, which is broadly used for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia is effective on EBV-positive B cell malignancies, using lymphoblastoid cell lines (LCLs) in vitro and in vivo. As a result, in vitro experiments showed that dasatinib induced cell death of the EBV-LCLs which was not accompanied with a lytic reactivation of EBVs. To evaluate the effectiveness in EBV latency type III represented by immunodeficiency lymphoma, LCL-inoculated immunodeficient NOD/shi-scid/Il2rg

Indexed as

Herpesvirus 4, HumanAnimalsCell Cycle CheckpointsCell DeathCell Line, TransformedDasatinibDisease Models, AnimalDisease SusceptibilityEpstein-Barr Virus InfectionsHeterograftsHumansMicePhosphorylationProtein Kinase InhibitorsSplenomegalyDasatinibProtein Kinase Inhibitors

Identifiers

PMID32152351
PMCPMC7062761
OpenAlexW3010193287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.